US 12,466,867 B2
Methods for activation and expansion of natural killer cells and uses thereof
Lucila Nassif Kerbauy, Houston, TX (US); Elizabeth Shpall, Houston, TX (US); and Katy Rezvani, Houston, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by Board of Regents, The University of Texas System, Austin, TX (US)
Filed on Jun. 23, 2021, as Appl. No. 17/304,585.
Application 17/304,585 is a continuation of application No. 16/970,937, previously published as PCT/US2019/019019, filed on Feb. 21, 2019.
Claims priority of provisional application 62/633,592, filed on Feb. 21, 2018.
Prior Publication US 2022/0118013 A1, Apr. 21, 2022
Int. Cl. C07K 14/54 (2006.01); A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/42 (2025.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C12N 5/0783 (2010.01)
CPC C07K 14/5434 (2013.01) [A61K 40/15 (2025.01); A61K 40/31 (2025.01); A61K 40/35 (2025.01); A61K 40/4211 (2025.01); A61K 40/4217 (2025.01); C07K 14/5443 (2013.01); C07K 14/55 (2013.01); C07K 14/70592 (2013.01); C07K 14/70596 (2013.01); C12N 5/0646 (2013.01)] 10 Claims
OG exemplary drawing
 
1. A method for treating cancer in an individual in need thereof, comprising administering to the individual in need thereof a therapeutically effective amount of ex vivo-combined pre-activated NK cells and a monoclonal, bispecific, or trispecific antibody, wherein the antibody binds an NK cell receptor to redirect the NK cells to a target tumor cell, wherein
(a) the NK cells are produced by the step of pre-activating the population of NK cells in a pre-activation culture comprising an effective concentration of IL-12, IL-15, and IL-18 to obtain pre-activated NK cells and then
(b) expanding the pre-activated NK cells in an expansion culture comprising artificial antigen presenting cells (aAPCs) expressing CD 137 ligand.